Many in the biopharma sector will rue the departure of Scott Gottlieb, an FDA commissioner who pursed a permissive path for novel drugs at the US regulator. Will his…
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.